# Molybdenum

> Molybdenum is an essential trace mineral required for the enzymes that detoxify sulfites and aldehydes. Sulfite metabolism issues are a recognized trigger for mast cell degranulation in MCAS, and most multivitamins skip molybdenum entirely. ZebraThrive uses 150 mcg daily in the PM stack.

**Page:** https://www.wellnessforzebras.com/ingredients/molybdenum
**Brand:** ZebraThrive
**Author:** Ken Chapman, Founder of ZebraThrive
**Last reviewed:** 2026-05-11
**Daily dose:** 150 mcg daily (PM capsules)
**Form used:** Molybdenum Glycinate (Chelate)
**Target population:** Adults 18+ with hypermobile Ehlers-Danlos Syndrome (hEDS), Postural Orthostatic Tachycardia Syndrome (POTS), or Mast Cell Activation Syndrome (MCAS).
**Regulatory framing:** US DSHEA dietary supplement. These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

## Key benefits

- Essential cofactor for Sulfite Oxidase (sulfite → sulfate)
- Reduces chemical sensitivity in MCAS patients
- Indirectly stabilizes mast cells by reducing sulfite burden
- Supports aldehyde detoxification (alcohol/aldehyde processing)

## What it is

An essential trace mineral required for enzymes that detoxify sulfites and aldehydes

## Why we include it

Supports sulfite metabolism-addressing a root trigger for mast cell degranulation in 60% of MCAS patients

## Plain-language summary

Molybdenum is an essential trace mineral and the cofactor for several oxidase enzymes - most importantly sulfite oxidase (which converts toxic sulfite to safe sulfate), xanthine oxidase (purine metabolism), and aldehyde oxidase (acetaldehyde and other aldehyde clearance). For the triad, molybdenum is especially relevant because sulfite oxidase activity matters for MCAS patients who react to dietary sulfites, and aldehyde clearance overlaps with histamine metabolism and alcohol/wine reactions. We dose 150 mcg as molybdenum glycinate - well within the supplement range and below the safety threshold.

## Mechanism

Molybdenum is the mandatory cofactor for Sulfite Oxidase. Sulfite accumulation is a recognized trigger for mast cell degranulation in MCAS, and converting sulfite to sulfate is what removes that trigger. Molybdenum is also the cofactor for Aldehyde Oxidase, which clears acetaldehyde (the metabolite that drives most wine and alcohol reactions in sensitive patients). Two distinct MCAS-relevant detox pathways from one trace mineral.

## Condition-specific notes

### MCAS (Mast Cell Activation Syndrome)

Primary indication. Stabilizes mast cells indirectly by clearing sulfite burden. Addresses reactions to wine, dried fruits, and environmental chemicals.

### hEDS (hypermobile Ehlers-Danlos Syndrome)

Sulfite accumulation can damage collagen cross-links; molybdenum helps preserve tissue integrity through detoxification.

### POTS (Postural Orthostatic Tachycardia Syndrome)

Reduces total body load of inflammatory triggers, helping to reduce the frequency of tachycardia flares and chemical-induced crashes.

## Why this form

**Selected form:** Molybdenum Glycinate (Chelate)

90-95% absorption compared to 57% for sodium forms. TRAACS chelated forms are best tolerated and avoid ammonia-sensitivity risks.

**Form comparison:**

| Form | Notes | Selected |
|---|---|---|
| Molybdenum Glycinate | 90-95% absorption; best tolerability; ammonia-free | Yes |
| Sodium Molybdate | Common alternative; lower (57-88%) absorption rate | No |

## Dose protocol

| Step | Dosage | Notes |
|---|---|---|
| Week 1 | 75 mcg (EOD) | Every other day for sensitive start |
| Week 2 | 75 mcg daily | Assess tolerance |
| Week 3+ | 150 mcg daily | Full target dose (PM) |

**Timeline to effect:** Chemical sensitivity improvements typically seen within 2-4 weeks.

## Evidence summary

### Sulfite Oxidase Cofactor Function

Molybdenum is required for the molybdenum cofactor (Moco) that activates sulfite oxidase (SUOX), the mitochondrial enzyme that converts toxic sulfite to sulfate. Loss of SUOX function produces severe neurological disease; partial Moco availability is a plausible factor in sulfite sensitivity reported by some MCAS patients.

- [1] **Claerhout H et al., "Isolated sulfite oxidase deficiency".** Design: Literature review of 47 isolated sulfite oxidase deficiency patients. Finding: Loss of SUOX function (homozygous mutations) produces severe pharmacoresistant seizures, neurological impairment, and sulfite/S-sulfocysteine accumulation; establishes Moco-SUOX axis as critical to sulfite handling. PMID: 28980090.
- [2] **Kaczmarek AT et al., "A defect in molybdenum cofactor binding causes an attenuated form of sulfite oxidase deficiency".** Design: Mechanistic biochemistry + clinical genetics, novel SUOX variant. Finding: Moco insertion into SUOX is the rate-limiting step in enzyme maturation; defects in Moco binding produce attenuated SUOX deficiency phenotypes. PMID: 34741542.
- [3] **Schwahn BC et al., "Molybdenum cofactor deficiency review".** Design: Clinical review of MoCD. Finding: Comprehensive review of molybdenum cofactor biosynthesis and its role in SUOX, xanthine oxidase, and aldehyde oxidase function. PMID: 38234320.

### Chemical Intolerance and the MCAS Connection

Chemical intolerance, in which patients report symptoms to low-dose environmental chemicals, is over-represented in MCAS. Molybdenum is the cofactor for the three xenobiotic-handling oxidases (sulfite oxidase, aldehyde oxidase, xanthine oxidase).

- [4] **Kohn JR et al., "MCAS, chemical sensitivity, and nutrition".** Design: Clinical review, prevalence and mechanism analysis. Finding: MCAS patients show high rates of multiple chemical sensitivity; nutrient cofactors for xenobiotic metabolism (including molybdenum) are relevant supportive options. PMID: 31845133.

## Evidence gaps

No direct trials in isolated hEDS/POTS populations. Use is primarily based on enzyme biochemistry and MCAS clinical observation.

## Safety

**Side effects:** Low risk. Some users report mild GI changes during the first 1-2 weeks as sulfite-processing pathways recalibrate. Stabilizes mast cells.

**Interactions:** Separate from Iron, Zinc, and Copper by 2-4 hours; can reduce copper absorption long-term. Enhances acetaminophen metabolism.

**Cautions:** Monitor copper status with high-dose, long-term use.

**Excipients to avoid:** Yeast-derived forms, Titanium dioxide, Magnesium stearate

**Excipients that are safe:** HPMC capsules, L-leucine, Rice flour

## Frequently asked questions

### Why is molybdenum important for MCAS?

Molybdenum is the cofactor for sulfite oxidase - the enzyme that converts sulfite to sulfate (the safe form). Many MCAS patients react to dietary sulfites (wines, dried fruits, processed foods). The reaction isn't always classical IgE-mediated; some of it is direct mast cell triggering by sulfite itself. Adequate molybdenum supports sulfite oxidase activity, which means dietary sulfites get cleared faster. Aldehyde oxidase (also molybdenum-dependent) clears acetaldehyde, the metabolite that drives most wine reactions. Two MCAS-relevant pathways from one mineral.

### Is 150 mcg of molybdenum safe?

Yes. The Recommended Dietary Allowance is 45 mcg/day; the Tolerable Upper Intake Level is 2,000 mcg/day. Our 150 mcg sits about 3-4 times above basic intake and over 13 times below the UL - comfortable safety margin. Molybdenum has very low oral toxicity; most adverse effects in the literature come from industrial exposure or extreme supplementation (10,000+ mcg). At 150 mcg, decades of supplement use have shown no clinical safety concerns in non-cholestatic individuals.

### Will molybdenum interact with my medications?

Molybdenum has a clean interaction profile at supplement doses. Very high doses (1,000+ mcg) can theoretically interact with copper metabolism over time, but our 150 mcg is far below that threshold and our formulation already includes 2 mg of copper. No documented interactions with the standard POTS, MCAS, or hEDS medication stack. Allopurinol is a xanthine oxidase inhibitor and molybdenum is the cofactor - high-dose molybdenum could theoretically oppose allopurinol's mechanism, but not at our dose.

### Why molybdenum glycinate vs other forms?

Glycinate is the chelated form - molybdenum bound to glycine, the simplest amino acid. The chelation provides better absorption through amino acid transporters and reduces GI irritation compared to inorganic molybdate salts. Bioavailability of molybdenum glycinate is consistently higher than sodium molybdate in absorption studies. The amino acid carrier approach is the same principle we use for copper bisglycinate, manganese bisglycinate, and magnesium bisglycinate - well-tolerated, well-absorbed chelates that don't compete with other minerals.

## References

[1] Claerhout H et al.. (2017). Isolated sulfite oxidase deficiency. PMID: 28980090. https://pubmed.ncbi.nlm.nih.gov/28980090/
[2] Kaczmarek AT et al.. (2021). A defect in molybdenum cofactor binding causes an attenuated form of sulfite oxidase deficiency. PMID: 34741542. https://pubmed.ncbi.nlm.nih.gov/34741542/
[3] Schwahn BC et al.. (2024). Molybdenum cofactor deficiency review. PMID: 38234320. https://pubmed.ncbi.nlm.nih.gov/38234320/
[4] Kohn JR et al.. (2020). MCAS, chemical sensitivity, and nutrition. PMID: 31845133. https://pubmed.ncbi.nlm.nih.gov/31845133/